Table 1.

Abbreviations: PI, patients improved, FU, follow–up (months); IPSS, International Prostate Symptoms Score; QoL, quality of life; Qmax, maximum urinary flow rate; PV, prostate volume; PVR, post–void residual volume; NA, not available.

Study	PSA(ng/ml)	PVR(ml)	PV (ml)	Qmax (ml/s)	QoL	IPSS	PI	FU
Maria et al; [31 ]	3.7 to 1.8; 51%, p=0.00001	126.3 to 21; 83%, p=0.00001	52.6 to 16.8; 68%, p<0.00001	8.1 to 15.4; p<0.00001		23.2 to 8,65%, p=0.00001	13(15)	2
Chuang et al; [18 ]	NA	177.6 to 24.5,86.2%, p=0.064	61.6 to 50; 18.8%, p<0.05	7..5 to 12.9; 72%, p<0.05	3.9 to 2.1; 61.5%, p<0.05	From 19 to 5,(73%, p<0.05)	8(8)	1
Chuang et al; [32 ]	0.8 to 0.72,NA	67.7 to 25.1; 63%, NA	19.6 to 17; 13.3%, p<0.0014	7.3 to 11.8; 39.8%, p<0.001	3.8 to 2.1; 44.7%, p<0.0001	18.8 to 8.9; 52.6%, p=0.0001	16(16)	1
Chuang et al; [33 ]	NA	64.2 to 35.7; 44%, p=0.3	21.1 to 18; 15%, p<0.001	7.9 to 12; 62%, p<0.001	3.9 to 2.1; 46%, p<0.001	18.7 to 9.8; 48%, p<0.001	100U	1
Chuang et al; [33 ]	NA	161.7 to 45.2; 72%, p=0.02	54.3 to 46.3; 15%, p<0.001	7 to 10.3; 47%,p<0.001	4.1 to 2; 51%, p<0.001	19.3 to 9.5; 51%, p<0.001	31(41)	1
Kuo; [35]	NA	243.5 to 36.8; p=0.005	65.5 to 49.6;p=0.009	7.6 to 11.6; p=0.05	4.5 to 2.1; p<0.0001	NA	10(10)	6
Park et al; [36 ]	2.6 to 2.4; NA	122.7 to 84.7; 34%, p<0.05	47.2 to 42; 13.1%, p<0.05	9.6 to 11.1; 15.5%, p<0.05	NA	24.3 to 16.9; 30.3%, p<0.05	39(52)	3
Silva et al; [34 ]	6 to 5; p=0.04	0 to 92	70 to 47; p<0.001	0 to 10.3	NA	NA	10(10)	3
Silva et al; [40 ]	25% decrease	55 to 82	82 to 49 (6m) then 73 (18m)	11.3 to 11.3	NA	10 to 12	11(11)	18
Brisinda et al ;[41 ]	6.2 to 4.8 p=0.03	92.1 to 80.3 P=0.01	54.1 to 47.2 p=0.01	8.6 to 13.1 p=0.01	NA	AUA 24.1 to 12.6 p=0.00001	41(77)	1
Brisinda et al ;[41 ]	6.2 to 3.0 p=0.00001	92.1 to 40.6 p=0.002	54.1 to 30.9 p=0000.1	8.6 to 16.5	NA	24.1 to 8.7 P=00001	55(77)	2
Brisinda et al ;[41 ]	3.0 to 3.1 p=0.7	40.6 to 27.1 p=0.03	30.9 to 26.9	16.5 to 14.5 p=0.03	NA	8.7 to 11.1 p=0.02	55+22(77)	30